In the meantime, Truist upgraded its Sangamo Therapeutics Inc [SGMO] rating to a Buy from a a Hold in a
As this happened, H.C. Wainwright reiterated its Sangamo Therapeutics Inc [SGMO] rating to a Buy in a research note published
Following these proceedings, RBC Capital Mkts downgraded its Sangamo Therapeutics Inc [SGMO] rating to a Sector perform from a an
As this happened, RBC Capital Mkts downgraded its Sangamo Therapeutics Inc [SGMO] rating to a Sector perform from a an
As this happened, RBC Capital Mkts downgraded its Sangamo Therapeutics Inc [SGMO] rating to a Sector perform from a an
Taking this into account, RBC Capital Mkts downgraded its Sangamo Therapeutics Inc [SGMO] rating to a Sector perform from a
Meanwhile, RBC Capital Mkts downgraded its Sangamo Therapeutics Inc [SGMO] rating to a Sector perform from a an Outperform in
While this happened, RBC Capital Mkts downgraded its Sangamo Therapeutics Inc [SGMO] rating to a Sector perform from a an
While this happened, RBC Capital Mkts downgraded its Sangamo Therapeutics Inc [SGMO] rating to a Sector perform from a an
Following these proceedings, RBC Capital Mkts downgraded its Sangamo Therapeutics Inc [SGMO] rating to a Sector perform from a an
